|
Articles
Build vs. Buy vs. Both
By Daniel C. Weaver
To contain costs and optimize performance, most drug discovery companies are faced with questions of "Build" vs. "Buy" with regard to their informatics systems. Here, the author describes an alternative: the hybrid "Both" approach to the software system development process.
Getting More out of Public Microarray Data
By Joel Parker
Current investigations into the transcriptome have yielded a vast amount of publicly available data, but the diversity of technologies used to isolate, purify, label and measure RNA can make it difficult to combine experiments. This month, guest author Joel Parker discusses successful methods for mining information from disparate data sets.
Is Genomics Advancing Drug Discovery?
By Lukas K. Buehler
Genomics has opened new ways of scrutinizing genes, which as created immense enthusiasm because of the potential of finding new cures for human diseases. here, our columnist explores the obstacles to the development and approval of novel drugs, and how we can overcome them through genomics.
How Multiplexed Arrays Enable Large-scale Studies
By John J. Kang , S. Shawn Dastmalchi , Ezra Abrams , Brian Patterson , J. Michael Collier
Discovery programs are beginning to incorporate hypothesis-driven research that calls for testing against large sample populations. This article describes how multiplexed arrays enable such an industrial approach to parallel analysis of target genes across large numbers of samples while offering improved reproducibility.
|
